Ascentage Pharma (06855) Discloses November Share Capital and Equity Movements

Bulletin Express12-04

Ascentage Pharma Group International (06855) released its monthly return on movements in securities for November 2025. The authorized share capital remained at 500,000,000 ordinary shares, each with a par value of USD 0.0001, totaling USD 50,000. No changes emerged in issued share capital: the number of issued ordinary shares stayed at 373,321,622. No treasury shares were recorded.

Under the Pre-IPO Share Option Scheme, 2,152,297 share options remained outstanding, with no new shares issued. The Post-IPO Share Option Scheme reflected an increase of 736,607 granted share options, 12,190 shares issuable under the scheme, and a total of 14,170,855 shares that may be issued upon exercise. No new shares were issued through the company's RSU Schemes, and 1,655,411 shares remained issuable under the 2022 RSU Scheme. No overall changes occurred in the number of issued or treasury shares for the month of November.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment